IS7564A - Lyfjablanda með breytta losun - Google Patents

Lyfjablanda með breytta losun

Info

Publication number
IS7564A
IS7564A IS7564A IS7564A IS7564A IS 7564 A IS7564 A IS 7564A IS 7564 A IS7564 A IS 7564A IS 7564 A IS7564 A IS 7564A IS 7564 A IS7564 A IS 7564A
Authority
IS
Iceland
Prior art keywords
modified release
medicinal product
medicinal
product
release
Prior art date
Application number
IS7564A
Other languages
English (en)
Inventor
Magnusson Anders
Thune Mikael
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7564A publication Critical patent/IS7564A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS7564A 2002-05-31 2004-11-29 Lyfjablanda með breytta losun IS7564A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201659A SE0201659D0 (sv) 2002-05-31 2002-05-31 Modified release pharmaceutical formulation
PCT/SE2003/000858 WO2003101424A1 (en) 2002-05-31 2003-05-27 Modified release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
IS7564A true IS7564A (is) 2004-11-29

Family

ID=20288037

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7564A IS7564A (is) 2002-05-31 2004-11-29 Lyfjablanda með breytta losun

Country Status (23)

Country Link
US (1) US7202236B2 (is)
EP (1) EP1513495A1 (is)
JP (2) JP4603353B2 (is)
KR (1) KR101166921B1 (is)
CN (2) CN101264051B (is)
AR (1) AR039936A1 (is)
AU (2) AU2003232870B2 (is)
BR (1) BR0311460A (is)
CA (1) CA2485535C (is)
EG (1) EG24479A (is)
IL (1) IL165029A0 (is)
IS (1) IS7564A (is)
MX (1) MXPA04011914A (is)
NO (1) NO20044767L (is)
NZ (1) NZ536621A (is)
PL (1) PL374299A1 (is)
RU (2) RU2474416C2 (is)
SA (1) SA03240402B1 (is)
SE (1) SE0201659D0 (is)
SG (1) SG165162A1 (is)
TW (2) TWI319317B (is)
WO (1) WO2003101424A1 (is)
ZA (1) ZA200409234B (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
EP1849004A1 (en) 2005-01-17 2007-10-31 Gyros Patent Ab A versatile flow path
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20080317789A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Carrageenan Process
US20080317791A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Kappa Carrageenan
US8268808B2 (en) * 2007-06-25 2012-09-18 Cp Kelco U.S., Inc. Carrageenan and carrageenan-containing products
US20080317926A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Carrageenan Process
US20080317790A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Process for Treatment of Kappa Carrageenan
US20080317927A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Process for Treatment of Kappa Carrageenan
WO2009002817A1 (en) * 2007-06-25 2008-12-31 Cp Kelco U.S., Inc. Carrageenan
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
US9125434B2 (en) * 2007-10-11 2015-09-08 Philip Morris Products S.A. Smokeless tobacco product, smokeless tobacco product in the form of a sheet, extrudable tobacco composition, method for manufacturing a smokeless tobacco product, method for delivering super bioavailable nicotine contained in tobacco to a user, and packaged smokeless tobacco product sheet
CN107048483A (zh) * 2007-10-11 2017-08-18 菲利普莫里斯生产公司 无烟烟草产品
US20090098192A1 (en) * 2007-10-11 2009-04-16 Fuisz Richard C Extrudable and Extruded Compositions for Delivery of Bioactive Agents, Method of Making Same and Method of Using Same
CA2706600A1 (en) * 2007-11-26 2009-06-04 Plant Bioscience Limited Novel polypeptides having endolysin activity and uses thereof
US8293285B2 (en) 2008-03-14 2012-10-23 Cp Kelco U.S., Inc. Carrageenan modified by ion-exchange process
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
GB0908949D0 (en) 2009-05-26 2009-07-01 Plant Bioscience Ltd Novel polypeptides having endolysin activity and uses thereof
DK3512495T3 (da) * 2016-09-15 2022-12-05 Camurus Ab Formuleringer af prostacyklinanaloger

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
CA1341029C (en) 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
TW201303B (is) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
NZ245039A (en) 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
WO1993018060A1 (en) 1992-03-04 1993-09-16 Gyógyszerkutató Intézet Kft. New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (is) 1992-03-06 1994-05-11 Hoffmann La Roche
US6984627B1 (en) 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5780631A (en) 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
AU1025795A (en) 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
EA199700186A1 (ru) 1995-02-17 1998-02-26 Басф Акциенгезельшафт Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
WO1996031504A1 (en) 1995-04-04 1996-10-10 Merck & Co., Inc. Thrombin inhibitors
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
JP2000514788A (ja) 1996-06-25 2000-11-07 イーライ・リリー・アンド・カンパニー 抗凝固剤
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
SE9802938D0 (sv) 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
DK1107791T3 (da) 1998-09-04 2007-09-03 Scios Inc Hydrogelpræparater til controlled release-administration af vækstfaktorer
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
AU764121B2 (en) 1999-01-13 2003-08-07 Astrazeneca Ab New amidinobenzylamine derivatives and their use as thrombin inhibitors
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
NZ523598A (en) 2000-08-16 2004-10-29 Astrazeneca Ab New amidino derivatives and their use as thrombin inhibitors
SE0003125D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
SE0102921D0 (sv) 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA78195C2 (uk) 2001-08-30 2007-03-15 Astrazeneca Ab Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation

Also Published As

Publication number Publication date
AU2003232870A1 (en) 2003-12-19
TW200913989A (en) 2009-04-01
JP4603353B2 (ja) 2010-12-22
NO20044767L (no) 2005-02-25
SA03240402B1 (ar) 2008-03-23
AR039936A1 (es) 2005-03-09
RU2004132856A (ru) 2005-08-10
SG165162A1 (en) 2010-10-28
MXPA04011914A (es) 2005-03-31
AU2003232870B2 (en) 2009-09-10
CN101264051A (zh) 2008-09-17
US20050171083A1 (en) 2005-08-04
CN100402025C (zh) 2008-07-16
BR0311460A (pt) 2005-03-29
TWI319318B (en) 2010-01-11
RU2352323C2 (ru) 2009-04-20
JP2005536472A (ja) 2005-12-02
CA2485535C (en) 2011-05-10
US7202236B2 (en) 2007-04-10
EG24479A (en) 2009-08-03
IL165029A0 (en) 2005-12-18
CN101264051B (zh) 2010-12-22
TWI319317B (en) 2010-01-11
RU2474416C2 (ru) 2013-02-10
CN1655761A (zh) 2005-08-17
PL374299A1 (en) 2005-10-03
SE0201659D0 (sv) 2002-05-31
AU2009243524A1 (en) 2009-12-24
TW200403992A (en) 2004-03-16
WO2003101424A1 (en) 2003-12-11
RU2008142261A (ru) 2010-05-10
KR101166921B1 (ko) 2012-07-23
CA2485535A1 (en) 2003-12-11
JP2009298795A (ja) 2009-12-24
EP1513495A1 (en) 2005-03-16
ZA200409234B (en) 2005-07-12
NZ536621A (en) 2006-10-27
KR20050010013A (ko) 2005-01-26

Similar Documents

Publication Publication Date Title
IS7564A (is) Lyfjablanda með breytta losun
DK1620118T3 (da) Reversible pegylerede lægemidler
HRP20130114T1 (xx) Farmaceutski oblik s brzim oslobađanjem sinakalcet hci
DE60324343D1 (de) Klettverschlussprodukt
NO20054681D0 (no) Farmasoytiske produkter
PT1501534E (pt) Formulacoes farmaceuticas
DE60332886D1 (de) Schnalle
DE602004017700D1 (de) Transmukosen verabreichung
DE50304897D1 (de) Gurtschloss
IS8327A (is) Módafíníl breyttar losaðar lyfjasamsetningar
DE60316390D1 (de) Schnalle
SK4325U (sk) Farmaceutická kompozícia s postupným uvoľňovaním
ATA7862003A (de) Prophylaxeartikel
DE60305728D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VERLuNGERTER FREISETZUNG
IS7582A (is) Hraðlosandi lyfjablanda
SE0301552L (sv) New product
NO20044188L (no) Kontrollerte frigjoringsdoseformer
EP1750693A4 (en) OKULOSELECTIVE MEDICINAL PRODUCTS AND PRODRUGS
DE60325920D1 (de) Schnalle
AU2003261067A8 (en) Modified release ketoprofen dosage form
FI20030830A0 (fi) Lääkevalmiste
DE112004001429D2 (de) Pharmazeutischer Wirkstoff
DE50309974D1 (de) Löseeinheit
UA7294S (uk) Упаковка фармацевтичного засобу
UA8578S (uk) Упаковка фармацевтичного засобу